Evidence map›Paper›PMID 36824133›Full record

ArticleFrontiers in oncology2023

Methylation-mediated silencing of

Peng Zhu, Xiang Li, Yujie Liu, Jing Xiong, Ding Yuan, Yan Chen, Lili Luo, Ju Huang, Binbin Wang, Quanfang Nie and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. International journal of molecular sciences · 2025
    Article
  2. DNMT Enzymes and Their Impact on Cervical Cancer: A State-of-the-Art Review.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Peng ZhuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Xiang LiDepartment of Gynaecology, The Third Xiangya Hospital, Central South University, Changsha, China.
Yujie LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Jing XiongDepartment of Gynaecology and Obstetrics, The Second Xiangya Hospital, Central South University, Changsha, China.
Ding YuanHealth Management Center, Xiangya Hospital, Central South University, Changsha, China.
Yan ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Lili LuoDepartment of Gynaecology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Ju HuangDepartment of Gynaecology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Binbin WangDepartment of Obstetrics and Gynecology, Loudi Central Hospital, Loudi, China.
Quanfang NieDepartment of Obstetrics and Gynecology, Loudi Central Hospital, Loudi, China.
Shuli WangDepartment of Obstetrics and Gynecology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Liying DangDepartment of Obstetrics and Gynecology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Shu LiXiangya Medical Laboratory, Central South University, Changsha, China.
Yan ShuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Lan FanDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Qing LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNLoudi Central Hospital · CNZhengzhou Central Hospital · CNFirst Affiliated Hospital of Shantou University Medical College · CNShantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer (CC) remains one of the leading causes of cancer-related deaths worldwide. However, cervical cancer is preceded by the pre-malignant cervical intraepithelial neoplasia (CIN) that can last for up to 20 years before becoming malignant. Therefore, early screening is the key to prevent the progression of cervical lesions into invasive cervical cancer and decrease the incidence. The genes, down-regulated and hypermethylated in cancers, may provide potential drug targets for cervical cancer. In our current study, using the datasets from Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases, we found that endothelin 3 (

Indexed as

biomarkercervical cancerCINDNA methylationEDN3

Identifiers

PMID36824133
PMCPMC9942821
OpenAlexW4319079306

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.